Li Yan-Bing, Wang Zhi, Zuo Hong-Bo, Li Li-Bo
Department of Oncology, Jiujiang No.1 People's Hospital, Jiujiang 332000, Jiangxi Province, China.
Department of Oncology, TCM-Integrated Hospital of Southern Medical University, Guangzhou 510310, Guangdong Province, China,E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Feb;29(1):104-108. doi: 10.19746/j.cnki.issn.1009-2137.2021.01.017.
To investigate the correlation between FOXP3, CD11c protein expression and the prognosis of patients with diffuse large B-cell lymphoma (DLBCL).
This study included 48 patients with DLBCL who were admitted to Jiujiang No.1 People's Hospital and TCM-Integrated Hospital of Southern Medical University from January 2015 to January 2019. The DLBCL tissues removed during the operation were collected as test specimens. The expression of FOXP3 and CD11c protein were detected by immunohistochemistry. The deadline for postoperative follow-up was December 31, 2019, and the patient's short-term efficacy (complete remission, partial remission) and progression-free survival were recorded.
FOXP3 protein was positively expressed in the nucleus, mostly focally or diffusely distributed, the FOXP3 rate was 54.17% (26/48). While, the CD11c protein was positively expressed on the cell membrane, mostly diffusely distributed, and the CD11c rate was 60.47% (29/48). The expression of FOXP3 and CD11c protein was no significant relationship with age, sex, site of involvement, and lactate dehydrogenase level in DLBCL patients, but was a significant relationship with clinical stage and international prognostic index score, the difference was statistically significant (P<0.05). That was, the lower the clinical stage of DLBCL patients and international prognostic index score, the higher the positive expression rate of FOXP3 and CD11c protein (r=0.637, r=0.709). One year after surgery, the total effective rate of DLBCL patients with FOXP3 or CD11c expression was significantly higher than that of patients with FOXP3 or CD11c,expression (P<0.05). By the end of the follow-up, the median progression-free survival of DLBCL patients with FOXP3 or CD11c expression was significantly longer than that of patients with FOXP3 or CD11c expression (P<0.05).
In some patients with DLBCL, FOXP3 and CD11c expresse positively, and the positive expression rate is related to the clinical stage and international prognostic index score. The positive expression of FOXP3 and CD11c indicate a good prognosis.
探讨叉头框蛋白3(FOXP3)、CD11c蛋白表达与弥漫性大B细胞淋巴瘤(DLBCL)患者预后的相关性。
本研究纳入2015年1月至2019年1月在九江市第一人民医院及南方医科大学中西医结合医院收治的48例DLBCL患者。术中切除的DLBCL组织作为检测标本。采用免疫组织化学法检测FOXP3和CD11c蛋白的表达。术后随访截止至2019年12月31日,记录患者的短期疗效(完全缓解、部分缓解)及无进展生存期。
FOXP3蛋白在细胞核中呈阳性表达,多为局灶性或弥漫性分布,FOXP3阳性率为54.17%(26/48)。而CD11c蛋白在细胞膜上呈阳性表达,多为弥漫性分布,CD11c阳性率为60.47%(29/48)。DLBCL患者FOXP3和CD11c蛋白的表达与年龄、性别、受累部位及乳酸脱氢酶水平无显著相关性,但与临床分期及国际预后指数评分有显著相关性,差异有统计学意义(P<0.05)。即DLBCL患者临床分期及国际预后指数评分越低,FOXP3和CD11c蛋白阳性表达率越高(r=0.637,r=0.709)。术后1年,FOXP3或CD11c表达阳性的DLBCL患者总有效率显著高于FOXP3或CD11c表达阴性的患者(P<0.05)。随访结束时,FOXP3或CD11c表达阳性的DLBCL患者中位无进展生存期显著长于FOXP3或CD11c表达阴性的患者(P<0.05)。
部分DLBCL患者中FOXP3和CD11c呈阳性表达,且阳性表达率与临床分期及国际预后指数评分相关。FOXP3和CD11c的阳性表达提示预后良好。